Switzerland: Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy.
The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fuelled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverages.
